Quantcast

Latest Agonist Stories

2014-04-30 12:31:18

Structures of human P2Y12 receptor key to next generation of antithrombotic drugs SHANGHAI, April 30, 2014 /PRNewswire/ -- An international team led by scientists at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM) has found the detailed structure of a receptor that plays a key role in platelet activation and blood clotting. The work has implications for treatment of cardiovascular and other diseases. In a pair of papers published by the journal Nature on...

2014-02-04 23:27:02

Patients that are concerned with uneven eyebrows now have an alternative to surgery – Botox. BotoxJuvedermDoctor.com explains how the procedure works and what patients can expect. (PRWEB) February 04, 2014 As noted by BotoxJuvedermDoctor.com both liquid brow lifts and treatments for evening out eyebrows are fairly simple procedures that have minimal risks and recovery time. Botox treatment for uneven eyebrows can be done with a single injection in the matter of minutes. The medical...

2011-09-02 12:19:40

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically (off-label) to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation. It has been postulated that opioid receptor blockade by LDN provokes a compensatory elevation in endogenous opioids and opioid receptors that can function after LDN is no...

2011-03-10 23:41:28

Scientists from The Scripps Research Institute have determined a new structure from a medically important superfamily of proteins. The structure should help instruct the design of a new kind of therapeutics for conditions ranging from Parkinson's disease to inflammation. The study, published on March 10, 2011, in Science Express, an advance, online publication of selected research from the journal Science, provides important insights into how this large family of proteins, called G...

2010-12-10 07:00:00

SAN DIEGO, Dec. 10, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH. "An orally bioavailable prostacyclin receptor agonist could improve the standard of care for patients with PAH, a life-threatening disorder," said William R. Shanahan,...

2010-12-07 06:30:00

MIAMI and EVANSTON, Ill., Dec. 7, 2010 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, reported that data being presented today at the 49th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) further confirm that its lead antidepressant candidate GLYX-13 appears free of the behavioral impairment and abuse potential that have limited the clinical utility of other NMDA receptor...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related